Fresenius Medical Care, a German group and world leader in services and products for the treatment of kidney failure, has just chosen its French industrial subsidiary in Arbresle (Rhône) to open a new production unit for a very high-tech product (dialysis fibre).

This is a major investment project worth 70 million Euros, which will create 80 new jobs.

The project should be completed in three years as it requires the acquisition of new land next to the current factory and the construction of several buildings in order to house the first three lines of the production unit, followed by two further production lines the year after.

It is also an innovation project for Fresenius Medical Care SMAD, as the production of the fibres needs very high- level specific technology and know-how which is only available at a few of Fresenius’ global sites.

Others of the group’s sites were also candidates for this project, including sites in Japan, USA and Germany, but it was the Arbresle site in the Lyon region that won the competition.

 

This new production unit will allow engineers, technicians, team leaders and qualified operator to be recruited and will require an appropriate training plan – the Arbresle site will therefore become part of the growth and evolution of the Biotechnology sector that is already well underway.